Formulation and Evaluation of Sustained Release Matrix Tablets of Ciprofloxacin HCL Using Gum Kondagogu and Chitosan as Matrix Forming Polymers”

摘要

Hepatitis B virus (HBV) infects around 350 million of the global population. The current antivirals are laden with side effects as well as expense burden. An alternative medication based on Ayurveda is being proposed to counter this scenario. Hep-1 to Hep-6 are herbal formulations used for the treatment of hepatitis B virus. They are also indicated for alleviation of hepatotoxicity. The molecular mechanism involved in the anti-HBV activity of these formulations is being studied using in-vitro models for the first time. Inhibition of Hepatitis B surface antigen (HBsAg) secretion from the transfected human hepatocarcinoma PLC/PRF/5 cells, as well as inhibition of the surface antigen binding was taken up in the present study. These anti-HBV activities were detected by HBsAg specific antibody-mediated enzyme assay (ELISA) at concentrations ranging from 50 to 250μg/mL. The results indicate that the suppression of HBsAg production and inhibition were best observed at 150μg/mL across the extracts. This concentration was used to determine the hepatoprotectivity of these extracts in a Kupffer cell-hepatocyte in-vitro co-culture; determined by the expression of cytokines TNF-α, IL-6 and IL-10, in presence of bacterial lipopolysaccharide. Hep-1 was found to be the most suitable formulation showing both anti-HBV activity and optimum hepatoprotectivity during the study. This extract could thus be beneficial in the treatment of liver inflammation.